Table 4.

Treatment-emergent adverse events by CTCAE grade in the safety population*

TEAEs	Severity, N (%)
	All grades	Grade 1	Grade 2	Grade 3	Grade 4
Hematologic toxicities (n = 25)
White blood cell count decreased	10(40.0)	3(12.0)	4(16.0)	3(12.0)	0(0)
Neutrophil count decreased	8(32.0)	1(4.0)	0(0)	3(12.0)	4(16.0)
Anemia	11(44.0)	7(28.0)	1(4.0)	3(12.0)	0(0)
Aspartate aminotransferase increased	6(24.0)	4(16.0)	2(8.0)	0(0)	0(0)
Alanine aminotransferase increased	7(28.0)	4(16.0)	3(120)	0(0)	0(0)
Blood bilirubin increased	3(12.0)	1(4.0)	2(8.0)	0(0)	0(0)
Creatinine increased	5(20.0)	4(16.0)	1(4.0)	0(0)	0(0)
Platelet count decreased	0(0)	0(0)	0(0)	0(0)	0(0)
Nonhematologic toxicities (n = 25)
Alopecia	23(92.0)	13(52.0)	10(40.0)	–	–
Fatigue	17(68.0)	8(32.0)	7(28.0)	2(8.0)	0(0)
Sensory peripheral neuropathy	15(60.0)	12(48.0)	2(8.0)	1(4.0)	0(0)
Anorexia	12(48.0)	7(28.0)	4(16.0)	1(4.0)	0(0)
Mucositis oral	9(36.0)	9(36.0)	0(0)	0(0)	0(0)
Motor peripheral neuropathy	8(32.0)	4(16.0)	4(16.0)	0(0)	0(0)
Diarrhea	7(28.0)	5(20.0)	2(8.0)	0(0)	0(0)
Arthralgia	6(24.0)	4(16.0)	2(8.0)	0(0)	0(0)
Myalgia	5(20.0)	4(16.0)	0(0)	1(4.0)	0(0)
Nausea	5(20.0)	5(20.0)	0(0)	0(0)	0(0)
Nail discoloration	4(16.0)	4(16.0)	–	–	–
Dysgeusia	4(16.0)	2(8.0)	2(8.0)	–	–
Rash	3(12.0)	3(12.0)	0(0)	0(0)	0(0)
Vomiting	3(12.0)	3(12.0)	0(0)	0(0)	0(0)
Edema limbs	3(12.0)	3(12.0)	0(0)	0(0)	0(0)
Lung infection	1(4.0)	0(0)	0(0)	1(4.0)	0(0)
Infusion-related reaction by pertuzumab	1(4.0)	0(0)	0(0)	1(4.0)	0(0)
Constipation	1(4.0)	1(4.0)	0(0)	0(0)	0(0)
Epistaxis	1(4.0)	1(4.0)	0(0)	0(0)	0(0)
Olfactory nerve disorder	1(4.0)	1(4.0)	0(0)	0(0)	0(0)
Nail loss	1(4.0)	1(4.0)	0(0)	–	–

*The safety population consisted of patients who received at least one dose of the study drugs

CTCAE common terminology criteria for adverse events